Literature DB >> 20688564

Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort study.

Eric A Engels1, Eo Rin Cho, Sun Ha Jee.   

Abstract

BACKGROUND: Hepatitis B virus (HBV) infection is common throughout Asia and Africa. Whether chronic HBV infection increases risk of non-Hodgkin lymphoma (NHL) is unclear. We aimed to assess the association between chronic HBV infection and subsequent development of NHL in a South Korean cohort.
METHODS: The Korean Cancer Prevention Study is a cohort study of South Korean workers and their dependants enrolled during 1992-95. From this cohort, we excluded individuals who died before Jan 1, 1993, who had cancer at or before the initial visit, who had missing information about weight, height, alanine aminotransferase or aspartate aminotransferase concentrations, or alcohol use, or who had evidence of HIV or HCV infection. Of 1,284,586 eligible participants, 603,585 had baseline data for serum hepatitis B surface antigen (HBsAg) status and were included in our study. We regarded HBsAg positivity at baseline as evidence of chronic HBV infection. Participants were followed up from baseline until Dec 31, 2006. We used national databases of inpatient and outpatient diagnoses and mortality records to ascertain occurrence of haematological malignancies. We assessed incidence of NHL overall and of NHL subtypes, malignant immunoproliferation, Hodgkin's lymphoma, multiple myeloma, and various leukaemias. We used Cox regression to evaluate associations with HBsAg status, adjusting for sex, age, and enrolment year.
FINDINGS: 53,045 (9%) of 603,585 participants tested positive for HBsAg at baseline. Subsequently, 133 HBsAg-positive and 905 HBsAg-negative individuals developed NHL. HBsAg-positive participants had an increased risk of NHL overall compared with those who were HBsAg-negative (incidence 19.4 vs 12.3 per 100,000 person-years; hazard ratio [HR] 1.74, 95% CI 1.45-2.09, adjusted for sex, age at baseline, and enrolment year). Among NHL subtypes, HBsAg positivity was associated with increased risk of diffuse large B-cell lymphoma (n=325, incidence 6.86 vs 3.79 per 100,000 person-years; adjusted HR 2.01, 1.48-2.75) and other or unknown subtypes (n=591, incidence 10.5 vs 7.07 per 100,000 person-years; adjusted HR 1.65, 1.29-2.11), compared with HBsAg negativity. Increased risk was also recorded for malignant immunoproliferation (n=14, incidence 0.44 vs 0.15 per 100,000 person-years; adjusted HR 3.79, 1.05-13.7). Risk of these malignancies was consistently raised in HBsAg-positive participants throughout 14 years of follow-up. HBsAg positivity was not associated with follicular or T-cell NHL, Hodgkin's lymphoma, multiple myeloma, or various leukaemias.
INTERPRETATION: During extended follow-up, HBsAg-positive individuals had an increased risk of NHL, suggesting that chronic HBV infection promotes lymphomagenesis. FUNDING: Korean Seoul City Research and the National Research and Development Program for Cancer Control, Ministry for Health, Welfare and Family Affairs, Republic of Korea; US National Cancer Institute. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20688564      PMCID: PMC2933963          DOI: 10.1016/S1470-2045(10)70167-4

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  34 in total

1.  Prevalence of hepatitis B or C virus infections in patients with non-Hodgkin's lymphoma.

Authors:  M Kuniyoshi; M Nakamuta; H Sakai; M Enjoji; N Kinukawa; K Kotoh; M Fukutomi; M Yokota; H Nishi; H Iwamoto; N Uike; J Nishimura; S Inaba; Y Maeda; H Nawata; K Muta
Journal:  J Gastroenterol Hepatol       Date:  2001-02       Impact factor: 4.029

Review 2.  Systematic review: regression of lymphoproliferative disorders after treatment for hepatitis C infection.

Authors:  J P Gisbert; L García-Buey; J M Pajares; R Moreno-Otero
Journal:  Aliment Pharmacol Ther       Date:  2005-03-15       Impact factor: 8.171

Review 3.  Chronic hepatitis B virus infection in Asian countries.

Authors:  I Merican; R Guan; D Amarapuka; M J Alexander; A Chutaputti; R N Chien; S S Hasnian; N Leung; L Lesmana; P H Phiet; H M Sjalfoellah Noer; J Sollano; H S Sun; D Z Xu
Journal:  J Gastroenterol Hepatol       Date:  2000-12       Impact factor: 4.029

4.  Cigarette smoking, alcohol drinking, hepatitis B, and risk for hepatocellular carcinoma in Korea.

Authors:  Sun Ha Jee; Heechoul Ohrr; Jae Woong Sull; Jonathan M Samet
Journal:  J Natl Cancer Inst       Date:  2004-12-15       Impact factor: 13.506

Review 5.  Extrahepatic manifestations of chronic hepatitis B.

Authors:  Steven-Huy B Han
Journal:  Clin Liver Dis       Date:  2004-05       Impact factor: 6.126

6.  Smoking and cancer risk in Korean men and women.

Authors:  Sun Ha Jee; Jonathan M Samet; Heechoul Ohrr; Jung Hee Kim; Il Soon Kim
Journal:  Cancer Causes Control       Date:  2004-05       Impact factor: 2.506

Review 7.  Strategy for vaccination against hepatitis B in areas with high endemicity: focus on Korea.

Authors:  Y O Ahn
Journal:  Gut       Date:  1996       Impact factor: 23.059

Review 8.  Prevalence of hepatitis B virus infection in non-Hodgkin lymphoma: a systematic review and meta-analysis.

Authors:  A Nath; R Agarwal; P Malhotra; S Varma
Journal:  Intern Med J       Date:  2010-09       Impact factor: 2.048

9.  Hepatitis B virus infection and B-cell non-Hodgkin's lymphoma in a hepatitis B endemic area: a case-control study.

Authors:  Jee Hyun Kim; Yung-Jue Bang; Byung Joo Park; Taiwoo Yoo; Chul Woo Kim; Tae-You Kim; Dae Seog Heo; Hyo-Suk Lee; Noe Kyeong Kim
Journal:  Jpn J Cancer Res       Date:  2002-05

10.  Epidemiological findings of hepatitis B infection based on 1998 National Health and Nutrition Survey in Korea.

Authors:  Duk-Hee Lee; Jin-Ha Kim; Jung-Ja Nam; Hye-Reon Kim; Hai-Rim Shin
Journal:  J Korean Med Sci       Date:  2002-08       Impact factor: 2.153

View more
  74 in total

1.  Lymphoid malignancies in U.S. Asians: incidence rate differences by birthplace and acculturation.

Authors:  Christina A Clarke; Sally L Glaser; Scarlett L Gomez; Sophia S Wang; Theresa H Keegan; Juan Yang; Ellen T Chang
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-04-14       Impact factor: 4.254

2.  Prevalence and clinical outcomes of hepatitis B virus infection in patients with aplastic anemia.

Authors:  Pan Zhao; Qing Gao; Qiulian He; Jing Tan
Journal:  Int J Hematol       Date:  2017-06-13       Impact factor: 2.490

3.  HBV reactivation risk factors in patients with chronic HBV infection with low replicative state and resolved HBV infection undergoing hematopoietic stem cell transplantation in Korea.

Authors:  Chung Hwan Jun; Ban Suk Kim; Chan Young Oak; Du Hyeon Lee; Eunae Cho; Sung Bum Cho; Sung Kyu Choi; Chang Hwan Park; Young Eun Joo; Je-Jung Lee; Hyeoung-Joon Kim
Journal:  Hepatol Int       Date:  2016-06-28       Impact factor: 6.047

Review 4.  KASL clinical practice guidelines for management of chronic hepatitis B.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2019-06-12

5.  A comparison of lamivudine vs entecavir for prophylaxis of hepatitis B virus reactivation in allogeneic hematopoietic stem cell transplantation recipients: a single-institutional experience.

Authors:  J Shang; H Wang; J Sun; Z Fan; F Huang; Y Zhang; Q Jiang; M Dai; N Xu; R Lin; Q Liu
Journal:  Bone Marrow Transplant       Date:  2016-01-11       Impact factor: 5.483

6.  Primary follicular lymphoma in a male breast: a case report.

Authors:  Seung Pil Jung; Kang Min Han; Seok Jin Kim; Seok Jin Nam; Jeoung Won Bae; Jeong Eon Lee
Journal:  Cancer Res Treat       Date:  2014-01-15       Impact factor: 4.679

7.  Differential expression of viral agents in lymphoma tissues of patients with ABC diffuse large B-cell lymphoma from high and low endemic infectious disease regions.

Authors:  Therese Högfeldt; Crystal Jaing; Kevin Mc Loughlin; James Thissen; Shea Gardner; Abeer A Bahnassy; Baback Gharizadeh; Joachim Lundahl; Anders Österborg; Anna Porwit; Abdel-Rahman N Zekri; Hussein M Khaled; Håkan Mellstedt; Ali Moshfegh
Journal:  Oncol Lett       Date:  2016-08-16       Impact factor: 2.967

8.  Genetic landscape of hepatitis B virus-associated diffuse large B-cell lymphoma.

Authors:  Weicheng Ren; Xiaofei Ye; Hong Su; Wei Li; Dongbing Liu; Mohammad Pirmoradian; Xianhuo Wang; Bo Zhang; Qiang Zhang; Longyun Chen; Man Nie; Yao Liu; Bin Meng; Huiqiang Huang; Wenqi Jiang; Yixin Zeng; Wenyu Li; Kui Wu; Yong Hou; Klas G Wiman; Zhiming Li; Huilai Zhang; Roujun Peng; Shida Zhu; Qiang Pan-Hammarström
Journal:  Blood       Date:  2018-03-15       Impact factor: 22.113

9.  Hepatitis B surface antigen seroconversion after HBV reactivation in non-Hodgkin's lymphoma.

Authors:  Wei-Ping Liu; Wen Zheng; Yu-Qin Song; Ling-Yan Ping; Gui-Qiang Wang; Jun Zhu
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

10.  HBsAg is an independent prognostic factor in diffuse large B cell lymphoma patients in rituximab era: result from a multicenter retrospective analysis in China.

Authors:  Zheng Wei; Shanhua Zou; Feng Li; Zhixiang Cheng; Junmin Li; Jianmin Wang; Chun Wang; Fangyuan Chen; Junning Cao; Yunfeng Cheng
Journal:  Med Oncol       Date:  2014-01-28       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.